Funding Opportunity Announcement by the National Institutes of Health Alcohol-PTSD Comorbidity: Preclinical Studies of Models and Mechanisms (R01)

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the NIH released an FOA on March 7, 2017. This funding opportunity, titled Alcohol-PTSD Comorbidity: Preclinical Studies of Models and Mechanisms," encourages Research Project Grant (R01) applications that will further the development, validation and/or application of animal models for mechanistic studies on the comorbidity of PTSD and alcohol use disorders.

FOA Number:

Funding Opportunity Title:
Alcohol-PTSD Comorbidity: Preclinical Studies of Models and Mechanisms (R01)

Participating Organizations:
National Institutes of Health (NIH)
Cohen Veterans Bioscience

Applications will be reviewed and considered for funding by NIAAA. After review, applicants are eligible for funding by Cohen Veterans Bioscience and will be able to submit their applications and summary statements for consideration.

Key Dates:
Submission for this opportunity open on April 17, 2017 with letters of intent due on this date and applications are due on May 17, 2017. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

For more information on how to apply and specific requirements, please visit and reference the application FOA number, RFA-AA-17-016.

Share this article:

More from CVB

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

New meta-analysis builds upon PTSD genetics research, providing a foundation for the development of precision therapies

Driving Progress: TBI Action Alliance Launches Multi-Pronged Initiative to Speed Development of Diagnostic and Therapeutic Solutions for Traumatic Brain Injury

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.